Upfront Immunotherapy for Metastatic Kidney Cancer
0 vistas
• 06/26/23
0
0
Empotrar
administrator
Suscriptores
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios